world health organization 1 pharmacovigilance dr shanthi pal quality assurance and safety of...
TRANSCRIPT
1World Health Organization
Pharmacovigilance
Dr Shanthi Pal
Quality Assurance and Safety of Medicines
WHO
2World Health Organization
Objectives
• To discuss the need for pharmacovigilance
• To present WHO’s role in promoting pharmacovigilance
3World Health Organization
Medicine Safety
• To undergo treatment you have to be very healthy, because apart from your sickness you have to stand the medicine.
Molière
4World Health Organization
Pharmacovigilance
What IS this?
5World Health Organization
Vigilance
Vigilare = to watch
alert watchfulness
forbearance of sleep; wakefulness
watchfulness in respect of danger; care; caution; circumspection
the process of paying close and continuous attention
6World Health Organization
Pharmacovigilance
• The science and activities relating to the detection, evaluation, understanding and prevention of adverse drug reactions or any other drug-related problems
7World Health Organization
Pharmacovigilance Major Aims
• early detection of unknown safety problems• detection of increases in frequency• identification of risk factors• quantifying risks• preventing patients from being affected
unnecessarily
Rational and Safe use of Medicines
8World Health Organization
• Pre-marketing safety data
Animal Experiments : Relevant?
Clinical Trials: Complete?
Why Pharmacovigilance?
9World Health Organization
Why Pharmacovigilance?
• Post-marketing Topics Unexpected adverse reactions Interactions Dependence Long-term efficacy, Resistance Risk factors Quality (Counterfeit) Cost assessment
10World Health Organization
Why Pharmacovigilance?
• Adverse Drug Reactions are the 4th to 6th largest cause of mortality in the USA
(Lazarou J. et al., 1998)
11World Health Organization
Why Pharmacovigilance?
The percentage of hospital admissions due to drug related events in some
countries is about or more than 10%.
• UK Study : 10.1 % (Bhalla et al, 2003)
• French study : 10.3 % prevalence of ADRs (Imbs et al, 1999)
12World Health Organization
Why Pharmacovigilance?
Economic impact
Drug related morbidity and mortality expenses exceeded US$ 177.4
billion in the USA in 2000
(Ernst & Grizzle, 2001)
13World Health Organization
WHO Programme for InternationalDrug Monitoring
WHOHQ
WHO CollaboratingCentre, Uppsala
NationalCentres
14World Health Organization
Mary CouperMedical Officer
Lembit RägoCoordinator QSM
Vladimir LepakhinADG/HTP
Caroline Mullen Secretary
Shanthi PalTechnical Officer
Christine EncrenazTechnical OfficerSCRIHS
Safety of Medicines TeamSafety of Medicines TeamSafety of Medicines TeamSafety of Medicines Team
15World Health Organization
WHO Programme for International Drug Monitoring (HQ)
• Policy
• Exchange of Information
• Technical support to countries
• Advisory Committee on Safety of Medicinal Products
16World Health Organization
Exchange of Information
• WHO Pharmaceuticals Newsletter• WHO Drug Alerts• WHO Drug Information• WHO Restricted Pharmaceuticals List• (Vigimed - electronic exchange)• (Uppsala Reports)• (Signal)
17World Health Organization
Technical support to countries
• Technical guidelines on all aspects of pharmacovigilance
(Several publications and documents)• Training courses on
pharmacovigilance
(Regional Training Courses, biennial course by UMC and HQ)
18World Health Organization
19World Health Organization
WHO Collaborating Centre (Uppsala Monitoring Centre)
ADR database• No of reports: more than 3 million• Each year increase ~250,000 / year• Top 5 reporting countries
• USA• United Kingdom• Germany• Australia• Canada
20World Health Organization
WHO Collaborating Centre (Uppsala Monitoring Centre)
ADR Reports• Analysis• Data mining (BCPNN)• Output
– Feedback to National Centres– Signal documents– Ad hoc research results
21World Health Organization
Future challenges
• Raise awareness
• Monitor all medicines
• Integrate work throughout WHO
• Improve training activities
22World Health Organization
In conclusion ….
• The work of WHO in the area of safety monitoring of medicines is necessary if we are to achieve the mission of EDM:
• Medicines should be Available, Affordable, Safe and Properly used.
23World Health Organization
Thank you
‘People who are vigilant do not die; people who are negligent are as if dead’.
- Shakyamuni Buddha